← Leaderboards
Shougang Zhuang
Medical University Of South Carolina
$5,657,209
Attributed
$6,036,800
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $659.2K · FY2006–25$1M$750K$500K$250K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,036,800 · 5
By mechanism
R01$5,936,800 · 4
R56$100,000 · 1
Top collaborators
- Zheng Dong2 shared
Most similar at Medical University Of South Carolina
Same institution · by research overlap
- Daniel J Herr$110,959
- Andre C. Eaddy$95,337
- Jason L Blum$75,106
Others in their field
Top investigators on “Mediating”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Lawrence Corey · Fred Hutchinson Cancer Center$493,822,581
- Barton F Haynes · Duke University$295,802,493
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$286,700,869
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$176,977,598
- Dan H. Barouch · Fred Hutchinson Cancer Center$122,734,499
Research focus
MediatingKidneyInjuryTubular FormationAttenuatedChronic Kidney FailureFibrosisEpithelial CellsPathway InteractionsSignal PathwayInhibitor/AntagonistPhosphorylationHistone Deacetylase InhibitorEpigenetic RegulationEpidermal Growth Factor ReceptorPhenotypeCellsInterstitialKidney FailureTherapeutic EffectG2/M ArrestIschemiaMolecularPharmaceutical Preparations
Grant awards (19)
Save Kidneys in Cisplatin Chemotherapy by blocking HDAC6$659,182
R01 · FY2025 · DK · contact PI
Save Kidneys in Cisplatin Chemotherapy by blocking HDAC6$100,000
R56 · FY2023 · DK · contact PI
Role of Histone Methyltransferase EZH2 in Acute and Chronic Renal Injury$361,890
R01 · FY2021 · DK · contact PI
Role of Histone Methyltransferase EZH2 in Acute and Chronic Renal Injury$365,238
R01 · FY2020 · DK · contact PI
Role of Histone Methyltransferase EZH2 in Acute and Chronic Renal Injury$367,024
R01 · FY2019 · DK · contact PI
Role of Histone Methyltransferase EZH2 in Acute and Chronic Renal Injury$367,024
R01 · FY2018 · DK · contact PI
Histone deacetylases as novel therapeutic targets for kidney fibrosis$357,750
R01 · FY2017 · DK · contact PI
Histone deacetylases as novel therapeutic targets for kidney fibrosis$357,750
R01 · FY2016 · DK · contact PI
Histone deacetylases as novel therapeutic targets for kidney fibrosis$357,750
R01 · FY2015 · DK · contact PI
Histone deacetylases as novel therapeutic targets for kidney fibrosis$357,750
R01 · FY2014 · DK · contact PI
Histone deacetylases as novel therapeutic targets for kidney fibrosis$306,273
R01 · FY2013 · DK · contact PI
Histone deacetylases as novel therapeutic targets for kidney fibrosis$317,382
R01 · FY2012 · DK · contact PI
Histone deacetylases as novel therapeutic targets for kidney fibrosis$317,382
R01 · FY2011 · DK · contact PI
Histone deacetylases as novel therapeutic targets for kidney fibrosis$386,250
R01 · FY2010 · DK · contact PI
Dedifferentiation Following Renal Cell Injury$262,002
R01 · FY2009 · DK · contact PI
Dedifferentiation Following Renal Cell Injury$262,002
R01 · FY2008 · DK · contact PI
Dedifferentiation Following Renal Cell Injury$251,194
R01 · FY2007 · DK · contact PI
Dedifferentiation Following Renal Cell Injury$203,838
R01 · FY2006 · DK · contact PI
Dedifferentiation Following Renal Cell Injury$79,119
R01 · FY2006 · DK · contact PI